FDA's Sunscreen Data Guidance Lacks Risk/Benefit Balance – Stakeholders
This article was originally published in The Rose Sheet
Executive Summary
FDA's proposal that sunscreen ingredient sponsors seeking GRASE status conduct maximal usage trials to assess potential for systemic absorption will delay consumer access to new broad-spectrum sunscreens without a sound scientific basis, PASS says in comments on FDA draft guidance. The American Cancer Society and American Academy of Dermatology Association express similar concerns.
You may also be interested in...
Systemic Exposure Data A MUsT For OTC Monograph Sunscreens, Other Topical Drugs In FDA Draft Guidance
Challenges posed by FDA-advised maximal usage trials have been the bane of OTC sunscreen and antimicrobial drug ingredient sponsors recently, but a draft guidance from the agency signals that those trials will be expected generally from companies looking to add topical ingredients to OTC drug monographs. CDER details its expectations for studies of ingredients’ absorption potential to inform systemic exposure and overall safety and efficacy conclusions.
Systemic Exposure Data A MUsT For OTC Monograph Sunscreens, Other Topical Drugs In FDA Draft Guidance
Challenges posed by FDA-advised maximal usage trials have been the bane of OTC sunscreen and antimicrobial drug ingredient sponsors recently, but a draft guidance from the agency signals that those trials will be expected generally from companies looking to add topical ingredients to OTC drug monographs. CDER details its expectations for studies of ingredients’ absorption potential to inform systemic exposure and overall safety and efficacy conclusions.
FDA’s MUsT Draft Guidance Extends Challenge To Wider OTC Drug Industry
It’s known that challenges posed by FDA-advised maximal usage trials have been the bane of OTC sunscreen and antimicrobial drug ingredient sponsors of late, but new draft guidance from the agency signals that MUsTs will be expected generally from companies looking to add topical ingredients to OTC drug monographs.